Amonafide

Summary

Amonafide (CHEMBL428676) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including acute myeloid leukemia and breast neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 3
• Chemistry: 283.32 Da · C16H17N3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL428676
Name	Amonafide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	50515
Molecular formula	C16H17N3O2
Molecular weight	283.32
InChIKey	UPALIKSFLSVKIS-UHFFFAOYSA-N

SMILES: CN(C)CCN1C(=O)C2=CC=CC3=CC(=CC(=C32)C1=O)N

IUPAC name: 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione

Also known as: Amonafida, Amonafide, AS-1413, Nafidimide, NSC-308847, amonafide, Amonofide, SID454647, AMONAFIDE

Parent form; salt/anhydrous children: CHEMBL538838, CHEMBL1910266, CHEMBL2104952

Patent coverage: 2,023 distinct patent families (8,237 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8,234 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Alpha-ketoglutarate-dependent dioxygenase FTO, Cytochrome P450 2D6.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
breast neoplasm	2	MONDO:0021100	MONDO:0007254

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00715637	PHASE3	UNKNOWN	Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study
NCT00074100	PHASE2	COMPLETED	Amonafide in Treating Women With Metastatic Breast Cancer That Has Progressed After Previous Chemotherapy
NCT01066494	PHASE2	UNKNOWN	A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).